Wednesday, February 10, 2010, 8:31am EST - Canadian Markets open in 59 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Response Genetics, Inc (RGDX)

 On Feb 9: 1.3199 USD   0.00 (0.00%)  
MORE ON RGDX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Response Genetics, Inc. (NCM:RGDX) Delayed quote dataEdit
Last Trade: 1.3199 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 1.3199
Open: N/A
Bid: 1.04 x 100
Ask: N/A
1y Target Est: 3.00
Day's Range: N/A - N/A
52wk Range: 0.29 - 2.72
Volume: 0
Avg Vol (3m): 8,587.3
Market Cap: 20.19M
P/E (ttm): N/A
EPS (ttm): -0.917
Div & Yield: N/A (N/A%)
Response Genetics, Inc (RGDX)
1d  5d  3m  6m  1y  2y  5y 
 Add RGDX to Portfolio   Download Data

HEADLINES
• RESPONSE GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Tue 5:09pm)
• Response Genetics to Present at the 20th Annual UBS Global Healthcare Services Conference and at the 12th Annual BIO CEO & Investor Conference
Business Wire (Wed, Feb 3)
• Response Genetics Announces Appointment of Dr. Edith P. Mitchell to Board of Directors
Business Wire (Tue, Jan 19)
• RESPONSE GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
EDGAR Online (Tue, Jan 19)
• Response Genetics to Increase Sales Force by 50 percent to Meet Growing Demand for its ResponseDX Tests
Business Wire (Mon, Jan 11)
• Response Genetics Inc. Announces Distribution Agreement with Genetic Technologies Ltd. to Expand the Availability of ResponseDX Molecular Diagnostic T
Business Wire (Wed, Jan 6)
• RESPONSE GENETICS INC Financials
EDGAR Online Financials (Fri, Nov 20)
• RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 16)
• Response Genetics, Inc. Reports Third Quarter 2009 Financial Results Driven by 100 Percent Increase in ResponseDX Revenues
Business Wire (Mon, Nov 16)
• Q3 2009 RESPONSE GENETICS INC Earnings Release - After Market Close
CCBN (Mon, Nov 16)
More Headlines for RGDX...
ANALYST
EPS Est (next year) (Dec-09) : N/A
EPS Est (in 2 years) (Dec-10) : N/A
Avg Rec (current)*: 3.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices